Cyclobenzaprine: Positive Opinion from EMA in Rapid Scientific Advice Procedure as a Possible Anti-Covid-19 Therapy
PR95117
MILAN, March 22, 2022, /PRNewswire=KYODO JBN/ --
M-Squared Consulting, a consultancy company for life sciences companies in the
management of pharmaceutical contracts, has received a first positive signal
from EMA's Pandemic Task Force in the Rapid Scientific Advice1 procedure for
potential treatments for Covid-19 in the repositioning project for
cyclobenzaprine, a drug for the treatment of acute musculoskeletal conditions.
Cyclobenzaprine, based on preclinical scientific evidence, has been shown to
inhibit viral replication by interfering in at least two steps of the infection
process - entry and replication - and to represent a novel therapeutic solution
for the treatment of Covid-19.
The mechanism of action intervenes in the infection process and the molecule
has the ability to reach the central nervous system, allowing the development
of an effective therapy for Neuro-Covid symptoms, whose efficacy against
variants will have to be verified.
“EMA's support is a milestone for the project, a milestone that marks a
fundamental starting point" says Manuel Bellasi, CEO of m-Squared -. We will
now continue with the research and development of what could be one of the most
promising treatments for Covid-19”.
References:
1. COVID-19 treatments that have received EMA advice
agenziafarmaco.gov.it)
Logo - https://mma.prnewswire.com/media/1771401/m_Squared_Consulting.jpg
Source: m-Squared Consulting S.r.L
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。